It was only last fall that Open AI’s ChatGPT thrust generative AI into the public psyche. Since then, many future-looking surveys have shown unease and trepidation competing hard for mindshare against hope and excitement.

The senior statistician purchased short-term stock options, including some that expired the next day, after allegedly being made aware of Paxlovid’s success in clinical trials ahead of a public announcement.

‘We need to design and build AI that helps healthcare professionals be better at what they do.’

Americans are somewhat more troubled than thrilled over AI’s mounting presence in modern life. But the collective outlook is a rich blend of both.

America’s two major political parties are talking in practical unison about working things out over a common cause.

The Drug Price Negotiation Program already has changed how the company considers the development of future oncology programs and medications. 

Today’s generative AI—namely ChatGPT-4—is pretty darned good at parsing out probable diseases in difficult-to-diagnose patient cases.

If healthcare AI is to flourish outside of academic research settings and industry R&D departments, it will need to win over its most difficult-to-impress audience: healthcare workers in hospitals.